
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
John Orwin, Genentech
S
Advertisement
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
Articles in this issue
almost 18 years ago
Mary Szela, Abbottalmost 18 years ago
Mightier Than the Swordalmost 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsalmost 18 years ago
Eric Floyd, Cephalonalmost 18 years ago
Nancy Phelan, Wyethalmost 18 years ago
Tightening the Chainalmost 18 years ago
Kurt Graves, Vertexalmost 18 years ago
Wendy Niebler, Shirealmost 18 years ago
Perfectly ImperfectAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
Pharma Funding Roundup: Violet Therapeutics' $4.75 Million Seed Extension Financing, Full-Life Technologies Completes $150 Million Financing
5




